|
WO2012058097A1
|
|
Downregulation of sine/alu retrotransposon transcription to induce or restore proliferative capacity and/or pluripotency to a stem cell
|
|
US2011081428A1
|
|
Use of thioflavin-like compounds to increase life span and/or health span
|
|
WO2011029053A1
|
|
Human embryonic stem cells for high throughout drug screening
|
|
WO2010017408A1
|
|
Caspase inhibitors and uses thereof
|
|
US2010099609A1
|
|
eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
|
|
WO2009105481A1
|
|
Mao-b elevation as an early parkinson's disease biomarker
|
|
US2008267874A1
|
|
Targeted Neuronal And Glial Human Embryonic Stem Cell Line
|
|
TW200820984A
|
|
Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
|
|
CN101443036A
|
|
Reagents and methods for cancer treatment and prevention
|
|
WO2007014156A2
|
|
Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease
|
|
WO2006132893A2
|
|
Sialic acid abc transporters in prokaryotes therapeutic targets
|
|
US2007269457A1
|
|
Immunotherapeutic compositions and methods
|
|
EP1786430A2
|
|
Small molecules that replace or agonize p53 function
|
|
US2006024691A1
|
|
Novel pathways in the etiology of cancer
|
|
AU2003223520A8
|
|
Targets for therapeutic intervention identified in the mitochondrial proteome
|
|
AU2002353891A1
|
|
Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
|
